JP2017527582A - Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法 - Google Patents

Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法 Download PDF

Info

Publication number
JP2017527582A
JP2017527582A JP2017513488A JP2017513488A JP2017527582A JP 2017527582 A JP2017527582 A JP 2017527582A JP 2017513488 A JP2017513488 A JP 2017513488A JP 2017513488 A JP2017513488 A JP 2017513488A JP 2017527582 A JP2017527582 A JP 2017527582A
Authority
JP
Japan
Prior art keywords
lif
ras
cancer
antibody
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527582A5 (enExample
Inventor
フランク マコーミック
フランク マコーミック
マン−ズー ワン
マン−ズー ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2017527582A publication Critical patent/JP2017527582A/ja
Publication of JP2017527582A5 publication Critical patent/JP2017527582A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017513488A 2014-09-10 2015-09-10 Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法 Pending JP2017527582A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048770P 2014-09-10 2014-09-10
US62/048,770 2014-09-10
PCT/US2015/049461 WO2016040657A1 (en) 2014-09-10 2015-09-10 TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2017527582A true JP2017527582A (ja) 2017-09-21
JP2017527582A5 JP2017527582A5 (enExample) 2018-10-18

Family

ID=55459579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513488A Pending JP2017527582A (ja) 2014-09-10 2015-09-10 Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法

Country Status (7)

Country Link
US (1) US20170247446A1 (enExample)
EP (1) EP3191129A4 (enExample)
JP (1) JP2017527582A (enExample)
CN (1) CN106687134A (enExample)
AU (1) AU2015314980A1 (enExample)
CA (1) CA2958685A1 (enExample)
WO (1) WO2016040657A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521274A (ja) * 2018-04-12 2021-08-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ がんの治療で使用するためのｌｉｆ阻害剤とｐｄ−１軸阻害剤との組み合わせ
JP2021523906A (ja) * 2018-05-14 2021-09-09 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Ｌｉｆに対する抗体及びそれらの投与形態
JP2021533084A (ja) * 2018-06-18 2021-12-02 メドイミューン・リミテッドMedImmune Limited 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
JP2022529824A (ja) * 2019-04-24 2022-06-24 メモリアル スローン ケタリング キャンサー センター Ｒａｓ変異体癌を治療するための組成物および方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US20190038367A1 (en) 2016-01-26 2019-02-07 Cyberdontics, Inc. Automated dental treatment system
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
FI3555132T3 (fi) 2016-12-19 2024-02-08 Medimmune Ltd Vasta-aineita LIF:iä vastaan ja niiden käyttöjä
CA3099429A1 (en) 2018-05-10 2019-11-14 Cyberdontics (Usa), Inc. Automated dental drill
CN116801810A (zh) 2020-09-03 2023-09-22 网络牙科(美国)公司 用于牙齿解剖结构的cna分析的方法和装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522756A (ja) * 2009-04-03 2012-09-27 フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2013523796A (ja) * 2010-04-05 2013-06-17 フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ バル デブロン（ウベアチェイーオー） ヒト白血病阻害因子（ｌｉｆ）を認識する抗体および望ましくない細胞増殖に関連する疾患の治療における抗ｌｉｆ抗体の使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014009289A (es) * 2012-02-01 2015-09-08 Compugen Ltd Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
WO2015040243A2 (en) * 2013-09-23 2015-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522756A (ja) * 2009-04-03 2012-09-27 フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2013523796A (ja) * 2010-04-05 2013-06-17 フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ バル デブロン（ウベアチェイーオー） ヒト白血病阻害因子（ｌｉｆ）を認識する抗体および望ましくない細胞増殖に関連する疾患の治療における抗ｌｉｆ抗体の使用

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521274A (ja) * 2018-04-12 2021-08-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ がんの治療で使用するためのｌｉｆ阻害剤とｐｄ−１軸阻害剤との組み合わせ
JP7423598B2 (ja) 2018-04-12 2024-01-29 メドイミューン・リミテッド がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ
JP2024054138A (ja) * 2018-04-12 2024-04-16 メドイミューン・リミテッド がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ
JP2021523906A (ja) * 2018-05-14 2021-09-09 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Ｌｉｆに対する抗体及びそれらの投与形態
JP7536654B2 (ja) 2018-05-14 2024-08-20 メドイミューン・リミテッド Ｌｉｆに対する抗体及びそれらの投与形態
JP2021533084A (ja) * 2018-06-18 2021-12-02 メドイミューン・リミテッドMedImmune Limited 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
JP7379390B2 (ja) 2018-06-18 2023-11-14 メドイミューン・リミテッド 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
JP2024023212A (ja) * 2018-06-18 2024-02-21 メドイミューン・リミテッド 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
JP7603772B2 (ja) 2018-06-18 2024-12-20 メドイミューン・リミテッド 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
JP2022529824A (ja) * 2019-04-24 2022-06-24 メモリアル スローン ケタリング キャンサー センター Ｒａｓ変異体癌を治療するための組成物および方法

Also Published As

Publication number Publication date
AU2015314980A1 (en) 2017-03-02
US20170247446A1 (en) 2017-08-31
EP3191129A4 (en) 2018-03-14
WO2016040657A1 (en) 2016-03-17
CN106687134A (zh) 2017-05-17
CA2958685A1 (en) 2016-03-17
EP3191129A1 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
JP2017527582A (ja) Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
US20250003005A1 (en) Detection of cancer
US9371568B2 (en) Markers associated with human double minute 2 inhibitors
US8357369B2 (en) Genetic markers for predicting responsiveness to combination therapy
Jimeno et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer
AU2018243754A1 (en) Methods of treating tumor
RU2728674C2 (ru) Экспрессия fgfr и чувствительность к ингибитору fgfr
AU2005267148A1 (en) Genetic markers for predicting disease and treatment outcome
US20210363593A1 (en) CXCL13 Marker For Predicting Immunotherapeutic Responsiveness In Patient With Lung Cancer And Use Thereof
EP3457138A2 (en) Novel biomarkers for acute myeloid leukemia
JP2016515141A (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
US20110236396A1 (en) Methods and compositions for diagnosing and treating a colorectal adenocarcinoma
CA3142662A1 (en) Compositions and methods for treating lung, colorectal and breast cancer
EP2557159A1 (en) Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma
Gürgen et al. A molecularly characterized preclinical platform of subcutaneous renal cell carcinoma (RCC) patient-derived xenograft models to evaluate novel treatment strategies
KR102800733B1 (ko) 담도암의 예방 또는 치료용 조성물
KR102759983B1 (ko) 대장암 환자에서 egfr-표적제제에 대한 내성 획득 관련 유전자 마커 및 이를 이용한 내성 획득의 예측 방법
US20210115521A1 (en) Method for inhibiting tumor progression or determining tumor progression state in gastric cancer
KR20250163523A (ko) 항 pd-1 면역관문 억제제에 대한 저항성 예측용 조성물
WO2023070121A1 (en) Compositions and methods for treatment of mic60 depleted cancers and metastasis
TW202231280A (zh) 抑制胃癌腫瘤生長或判斷胃癌腫瘤生長階段之方法
O'Leary A Demethylation Screen Identifies Novel Targets of Epigenetic Regulation in Lung Cancer
HK1256118B (en) Fgfr expression and susceptibility to an fgfr inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200316